Introduction
Immunoassay is the most widely used and largest market-share segment in the in vitro diagnostics (IVD) field. Based on the principle of antigen-antibody specific reactions, it hormones, tumor markers, infection markers, and other substances in samples, providing critical evidence for disease screening, diagnosis, treatment monitoring, and prognosis assessment. From central laboratories in tertiary hospitals to POCT (point-of-care testing) scenarios in primary healthcare facilities, from infectious disease screening to tumor marker detection, immunoassay technology is everywhere. The performance of high-quality immunoassay reagents heavily depends on the proper selection and combination of antigens, antibodies, enzymes, substrates, solid-phase carriers, blocking agents, stabilizers, preservatives, and other raw materials. As the general outline for the immunoassay raw material series, this article systematically introduces the core position of immunoassay in IVD, a comparison of the three major technology platforms, a panorama of core raw materials, and general principles for raw material selection, laying the foundation for subsequent in-depth platform-specific analyses.
I. Core Position of Immunoassay in IVD
1.1 Market Position of Immunoassay
Immunoassay is one of the largest and fastest-growing segments of the IVD market. According to industry data, immunoassay accounts for approximately 40-50% of the global IVD market, far exceeding clinical chemistry, molecular diagnostics, hematology, and other segments. Its main drivers include:
-
Increasing burden of chronic and infectious diseases: Growing demand for screening and monitoring of cancer, cardiovascular diseases, diabetes, hepatitis, HIV, and other conditions
-
Aging population: Elderly populations have significantly higher demand for immunoassay testing
-
Popularization of POCT technology: Rapid tests (LFA) have brought immunoassay from central laboratories to primary care and home settings
-
Emergence of new technology platforms: Fully automated high-throughput platforms such as CLIA and ECL have greatly improved detection efficiency and accuracy
1.2 Disease Areas Covered by Immunoassay
Immunoassay covers testing needs across virtually all clinical departments. The main application areas are as follows:
| Disease Area | Common Tests | Primary Technology Platforms |
|---|---|---|
| Infectious Diseases | HIV antibody/antigen, Hepatitis B panel (HBsAg, HBcAb, etc.), Hepatitis C antibody, Syphilis antibody, COVID-19 antibody/antigen | ELISA, CLIA, LFA |
| Tumor Markers | AFP (liver cancer), CEA (GI cancers), CA19-9 (pancreatic cancer), CA125 (ovarian cancer), PSA (prostate cancer), HE4 (ovarian cancer) | CLIA, ELISA |
| Cardiovascular Diseases | hs-cTnI, hs-cTnT, NT-proBNP/BNP (heart failure), CK-MB, Myo | CLIA, LFA |
| Thyroid Function | TSH, T3, T4, FT3, FT4, Thyroglobulin antibody, Thyroid peroxidase antibody | CLIA |
| Endocrinology/Hormones | Sex hormones (E2, P, T, FSH, LH), HCG, AMH, Insulin, C-peptide | CLIA |
| Autoimmune Diseases | ANA (antinuclear antibody), ds-DNA, RF (rheumatoid factor), CCP | ELISA |
| Inflammation/Infection Markers | CRP, PCT, IL-6, SAA | CLIA, LFA |
| Allergy Testing | Specific IgE | CLIA, ELISA |
| POCT Rapid Testing | COVID-19 antigen, Influenza A/B, Pregnancy (HCG), Drug screening | LFA |
1.3 Irreplaceability of Immunoassay in IVD
Compared with other IVD technologies, immunoassay has the following irreplaceable advantages:
| Comparison Item | Immunoassay | Clinical Chemistry | Molecular Diagnostics |
|---|---|---|---|
| Target | Proteins, hormones, antibodies | Metabolites, electrolytes, enzymes | Nucleic acids (DNA/RNA) |
| Sensitivity | High (fM-pM; CLIA can reach sub-fM) | Medium-high (μM-nM) | Extremely high (single copy) |
| Detection Time | 10 minutes - 2 hours | 5-30 minutes | 1-4 hours |
| Cost | Low-medium | Low | High |
| Operational Complexity | Medium | Low-medium | High |
| Applicable Scenarios | Nearly all clinical departments | Routine checkups, emergency | Pathogen detection, genotyping |
Core Conclusion: Immunoassay has an irreplaceable position in protein/hormone/antibody marker detection, complementing rather than replacing clinical chemistry and molecular diagnostics.
II. Comprehensive Comparison of the Three Major Immunoassay Technology Platforms
2.1 Platform Overview
| Technology Platform | Full Name | Signal Generation Principle | Signal Detection Method |
|---|---|---|---|
| ELISA | Enzyme-Linked Immunosorbent Assay | Enzyme (HRP/AP) catalyzes chromogenic substrate | Colorimetric (microplate reader) |
| CLIA | Chemiluminescence Immunoassay | Enzyme or direct label catalyzes chemiluminescent substrate | Chemiluminescence detector |
| LFA | Lateral Flow Assay / Immunochromatography | Gold nanoparticles/fluorescent microspheres for visualization | Visual/fluorescence reader |
2.2 Performance Parameter Comparison
| Comparison Item | ELISA | CLIA | LFA |
|---|---|---|---|
| Detection Sensitivity | pM-nM | fM-pM (as low as sub-fM) | nM-μM |
| Linear Range | 1-2 orders of magnitude | 3-6 orders of magnitude | 1-2 orders of magnitude |
| Detection Time | 1-3 hours | 15-30 minutes | 10-20 minutes |
| Automation Level | Semi-automated/Fully automated | Fully automated | Manual/Simple |
| Throughput | Medium-high (96-well plate) | High (continuous loading) | Low (single strip) |
| Equipment Cost | Low-medium (plate reader) | High (luminometer) | Very low (no instrument) |
| Reagent Cost | Low | High | Low-medium |
| Operational Complexity | Medium | Low-medium (automated) | Very low |
| Quantification Capability | Quantifiable | Quantifiable | Qualitative/Semi-quantitative |
| Primary Application Scenarios | Central laboratories | Central laboratories, emergency | POCT, primary care, home use |
2.3 Technical Advantages and Limitations
| Platform | Advantages | Limitations |
|---|---|---|
| ELISA | Classic and mature, low cost, high throughput, flexible operation | Lower sensitivity, long assay time, multiple steps |
| CLIA | Extremely high sensitivity, wide linear range, automated, high throughput | High equipment cost, high reagent cost |
| LFA | Fast, simple, no equipment needed, suitable for POCT | Low sensitivity, semi-quantitative, subjective interpretation |
2.4 Application Scenario Selection Guide
| Scenario | Recommended Platform | Rationale |
|---|---|---|
| Large hospital central laboratory, high sample volume | CLIA | High throughput, automated, accurate results |
| Small/medium laboratory, balancing cost and throughput | ELISA | Low cost, acceptable throughput |
| Emergency/ICU, requiring rapid reporting | CLIA (fully automated) | Fast (15-30 minutes), accurate |
| Primary care/community screening, no equipment available | LFA | No instrument needed, simple operation |
| Home self-testing (e.g., pregnancy, COVID-19) | LFA | Convenient, fast, no training required |
| Research experiments/small batch testing | ELISA | Flexible, controllable cost |
| Vaccine immunogenicity evaluation/neutralizing antibody testing | ELISA | Classic method, customizable |
III. Panorama of Core Raw Materials for Immunoassay
The performance of immunoassay reagents essentially depends on the proper selection and combination of the following four major categories of raw materials.
3.1 Core Biological Raw Materials — The "Soul" of Immunoassay
These are the "heart" of immunoassay, determining the specificity and sensitivity of the test.
| Raw Material Category | Specific Raw Materials | Function | Selection Points |
|---|---|---|---|
| Antigens | Recombinant antigens, natural antigens, synthetic peptides | Coating/detection of target antibodies | Purity ≥90%, high activity, batch consistency |
| Antibodies | Monoclonal antibodies, polyclonal antibodies | Capture/detection of target antigens | Affinity ≥10⁸ L/mol, high specificity |
| Standards/Controls | Recombinant proteins, natural proteins | Quantification standards, quality control | Traceable to international standards, good stability |
Key Indicators:
-
Affinity: The strength of antibody-antigen binding, directly affecting sensitivity. CLIA requires ≥10⁹ L/mol, ELISA requires ≥10⁸ L/mol.
-
Specificity: The ability of an antibody to bind to the target antigen without cross-reacting with other substances.
-
Lot-to-lot consistency: Stability of affinity and specificity across different production batches.
3.2 Signal System Raw Materials
| Raw Material Category | Specific Raw Materials | CAS No. | Main Application | Selection Points |
|---|---|---|---|---|
| Enzymes | HRP (Horseradish Peroxidase) | 9003-99-0 | ELISA/CLIA labeling | RZ≥3.0, ≥250 U/mg |
| AP (Alkaline Phosphatase) | 9001-78-9 | CLIA labeling | ≥1000 U/mg | |
| Chromogenic Substrates | TMB | 54827-17-7 | ELISA color development | ≥98%, low background |
| p-NPP | 4264-83-9 | AP chromogenic substrate | ≥98% | |
| Chemiluminescent Substrates | Luminol | 521-31-3 | HRP luminescent substrate | ≥98% |
| AMPPD/AMPPD | 122341-56-4 / 122320-73-4 | AP luminescent substrate | ≥98% | |
| Acridinium ester (AE) | 194357-63-8 | Direct labeling | ≥95% | |
| Signal Labels | Colloidal gold (20-40 nm) | — | LFA signal | Uniform particle size, monodisperse |
| Fluorescent microspheres | — | Fluorescent LFA | Size 100-300 nm, high fluorescence intensity |
3.3 Solid-Phase Carriers
| Raw Material Category | Specific Raw Materials | Main Application | Selection Points |
|---|---|---|---|
| ELISA Plates | High-binding polystyrene plates | Passive adsorption of coating antibodies/antigens | Binding capacity ≥300 ng/cm² |
| Magnetic Beads | Carboxyl/tosyl-activated magnetic beads (1-3 μm) | CLIA solid-phase carrier | Superparamagnetic, fast magnetic response, high loading capacity |
| NC Membrane | Nitrocellulose membrane (pore size 5-15 μm) | LFA solid-phase carrier | Moderate flow rate, high protein binding capacity |
| Conjugate Pad/Sample Pad | Glass fiber/polyester fiber | LFA consumables | Good release properties, low protein adsorption |
3.4 Reaction Environment Raw Materials
| Raw Material Category | Specific Raw Materials | CAS No. | Main Application | Recommended Concentration |
|---|---|---|---|---|
| Blocking Agents | BSA | 9048-46-8 | Blocks non-specific binding sites | 1-3% |
| Casein | 9000-71-9 | High-efficiency blocking | 0.5-2% | |
| Stabilizers | Trehalose | 6138-23-4 | Lyophilization/liquid protection | 2-5% |
| Sucrose | 57-50-1 | Protectant, promotes release | 5-10% | |
| PVP K30 | 9003-39-8 | Stabilizes colloidal gold | 1-2% | |
| Surfactants | Tween-20 | 9005-64-5 | Washing/flow | 0.05-0.5% |
| Triton X-100 | 9036-19-5 | Lysis/solubilization | 0.1-1% | |
| Preservatives | ProClin 300 | — | Broad-spectrum antimicrobial | 0.02-0.05% |
| Gentamicin | 1405-41-0 | Antibacterial | 0.005-0.01% | |
| Sodium azide | 26628-22-8 | ⚠️ Prohibited in HRP-containing reagents | 0.01-0.1% |
IV. General Principles for Immunoassay Raw Material Selection
4.1 Antibody Selection Principles
Antibodies are the most important core raw material in immunoassay, and their quality directly determines reagent performance.
| Principle | Explanation | Impact on ELISA/CLIA/LFA |
|---|---|---|
| High affinity | Affinity ≥10⁸ L/mol (ELISA) or ≥10⁹ L/mol (CLIA) | Determines lower limit of detection sensitivity |
| High specificity | No cross-reactivity with other proteins in the same family | Determines detection specificity, avoids false positives |
| Pairing compatibility | Capture and detection antibodies recognize different epitopes | Determines sandwich assay performance |
| Lot-to-lot consistency | Stable affinity and specificity across batches | Determines inter-batch variability of reagents |
| Storage stability | Long-term stability at 2-8°C or -20°C | Determines reagent shelf life |
4.2 Signal System Selection Principles
| Platform | Recommended Signal System | Rationale |
|---|---|---|
| ELISA | HRP + TMB | Classic and mature, sufficient sensitivity, low cost |
| CLIA | AP + AMPPD (or HRP + Luminol + enhancer) | Highest sensitivity, low background |
| CLIA (rapid) | Acridinium ester direct labeling | Flash luminescence, fast detection speed |
| LFA (visual) | Colloidal gold (20-40 nm) | Sufficient signal intensity, low cost |
| LFA (quantitative) | Fluorescent microspheres | Enables quantitative detection, higher sensitivity |
4.3 Stabilizer and Preservative Selection Principles
| Principle | Explanation | Recommendation |
|---|---|---|
| Enzyme activity protection | Protects HRP/AP activity in liquid or lyophilized state | Trehalose, BSA, glycerol |
| Antibody stability | Prevents antibody degradation and aggregation | BSA, trehalose, sucrose |
| Microbial control | Prevents microbial growth in aqueous reagents | ProClin 300 (preferred for HRP-containing reagents) |
| ⚠️ Critical Warning | Sodium azide inhibits HRP activity | Prohibited in HRP-containing reagents |
4.4 Regulatory and Quality Control Principles
| Principle | Explanation |
|---|---|
| Traceability | Standards traceable to international standards (WHO, IFCC) |
| Stability data | Provide accelerated and real-time stability data |
| Quality documentation | Provide COA, MSDS, technical datasheets |
| Regulatory support | Provide FDA DMF, CE, ISO13485 documentation |
4.5 Summary of Core Warnings
| Warning | Applicable Platforms | Reason |
|---|---|---|
| ⚠️ HRP-containing reagents must NOT use sodium azide | ELISA, CLIA (HRP system) | Sodium azide strongly inhibits HRP activity |
| ⚠️ CLIA magnetic beads avoid aggregation | CLIA | Aggregation leads to batch failure and abnormal results |
| ⚠️ LFA colloidal gold avoid aggregation | LFA | Gold sol aggregation leads to loss of sensitivity |
| ⚠️ NC membrane avoid moisture | LFA | Moisture leads to abnormal flow and detection failure |
V.Summary
Immunoassay is the most core and widely applicable technology segment in the IVD field, accounting for approximately 40-50% of the market share. Based on the principle of antigen-antibody specific reactions, it covers nearly all disease areas including infectious diseases, oncology, cardiovascular diseases, endocrinology, autoimmune diseases, and POCT, complementing clinical chemistry and molecular diagnostics.
艳 李
